BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26544868)

  • 1. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis.
    Budd WT; Seashols-Williams SJ; Clark GC; Weaver D; Calvert V; Petricoin E; Dragoescu EA; O'Hanlon K; Zehner ZE
    PLoS One; 2015; 10(11):e0142373. PubMed ID: 26544868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection.
    Zhang X; Ladd A; Dragoescu E; Budd WT; Ware JL; Zehner ZE
    Clin Exp Metastasis; 2009; 26(8):965-79. PubMed ID: 19771525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.
    Seashols-Williams SJ; Budd W; Clark GC; Wu Q; Daniel R; Dragoescu E; Zehner ZE
    PLoS One; 2016; 11(7):e0159601. PubMed ID: 27447934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
    Giangreco AA; Vaishnav A; Wagner D; Finelli A; Fleshner N; Van der Kwast T; Vieth R; Nonn L
    Cancer Prev Res (Phila); 2013 May; 6(5):483-94. PubMed ID: 23503652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2.
    Liang L; Li X; Zhang X; Lv Z; He G; Zhao W; Ren X; Li Y; Bian X; Liao W; Liu W; Yang G; Ding Y
    Gastroenterology; 2013 Mar; 144(3):624-635.e4. PubMed ID: 23201162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.
    Riquelme I; Tapia O; Leal P; Sandoval A; Varga MG; Letelier P; Buchegger K; Bizama C; Espinoza JA; Peek RM; Araya JC; Roa JC
    Cell Oncol (Dordr); 2016 Feb; 39(1):23-33. PubMed ID: 26458815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway.
    Yang W; Xie T
    Reprod Sci; 2020 Jan; 27(1):132-144. PubMed ID: 32046405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
    Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ
    Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
    Yang Y; Mei Q
    Mol Vis; 2015; 21():1307-17. PubMed ID: 26730174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
    He Y; Ge Y; Jiang M; Zhou J; Luo D; Fan H; Shi L; Lin L; Yang L
    Cell Physiol Biochem; 2018; 47(4):1465-1481. PubMed ID: 29949784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
    Wu Z; He B; He J; Mao X
    Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
    Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.
    Tang Y; Pan J; Huang S; Peng X; Zou X; Luo Y; Ren D; Zhang X; Li R; He P; Wa Q
    J Exp Clin Cancer Res; 2018 Jul; 37(1):160. PubMed ID: 30021600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Shi XB; Xue L; Ma AH; Tepper CG; Kung HJ; White RW
    Prostate; 2011 Apr; 71(5):538-49. PubMed ID: 20886540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.
    Feliciano A; Castellvi J; Artero-Castro A; Leal JA; Romagosa C; Hernández-Losa J; Peg V; Fabra A; Vidal F; Kondoh H; Ramón Y Cajal S; Lleonart ME
    PLoS One; 2013; 8(10):e76247. PubMed ID: 24098452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1.
    Han Y; Liu Y; Zhang H; Wang T; Diao R; Jiang Z; Gui Y; Cai Z
    FEBS Lett; 2013 Nov; 587(23):3875-82. PubMed ID: 24396870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.